Search research articles
Contact Us
Filters
Showing results (31-40 of 276) with videos related to
Page
of 28
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 26, 2012
Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer
Andreas du Bois, Christian Marth, Jacobus Pfisterer, et al.
Cancer Treatment Reviews
|
July 31, 2021
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations
Hélène Vanacker, Philipp Harter, Sana Intidhar Labidi-Galy, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 11, 2009
Compliance to consensus recommendations, surgeon's experience, and introduction of a quality assurance and management program: influence on therapy of early-stage ovarian carcinoma
Stefan Kommoss, Philipp Harter, Alexander Traut, et al.
Gynecologic Oncology
|
March 19, 2013
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG
Florian Heitz, Andreas du Bois, Philipp Harter, et al.
ESMO Open
|
December 14, 2020
First-line PARP inhibitors in ovarian cancer: summary of an <i>ESMO Open - Cancer Horizons</i> round-table discussion
Susana Banerjee, Antonio Gonzalez-Martin, Philipp Harter, et al.
Annals of Surgical Oncology
|
April 2, 2021
Association Between Adjuvant Therapy and Survival in Stage II-III Endometrial Cancer: Influence of Malignant Peritoneal Cytology
Koji Matsuo, Shinya Matsuzaki, David J Nusbaum, et al.
Investigational New Drugs
|
September 6, 2013
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)
Philipp Harter, Jalid Sehouli, Rainer Kimmig, et al.
Archives of Gynecology and Obstetrics
|
February 20, 2016
The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications
Ivo Meinhold-Heerlein, Christina Fotopoulou, Philipp Harter, et al.
Expert Review of Anticancer Therapy
|
July 24, 2013
Adjuvant therapy in node-positive vulvar cancer
Sven Mahner, Fabian Trillsch, Lilli Kock, et al.
Archives of Gynecology and Obstetrics
|
September 21, 2018
Is there a role for HIPEC in ovarian cancer?
Philipp Harter, Andreas du Bois, Jalid Sehouli, et al.
Page
of 28
Search research articles
Search
Showing results (31-40 of 276) with videos related to
Sort By:
Page
of 28
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 26, 2012
Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer
Andreas du Bois, Christian Marth, Jacobus Pfisterer, et al.
Cancer Treatment Reviews
|
July 31, 2021
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations
Hélène Vanacker, Philipp Harter, Sana Intidhar Labidi-Galy, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 11, 2009
Compliance to consensus recommendations, surgeon's experience, and introduction of a quality assurance and management program: influence on therapy of early-stage ovarian carcinoma
Stefan Kommoss, Philipp Harter, Alexander Traut, et al.
Gynecologic Oncology
|
March 19, 2013
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG
Florian Heitz, Andreas du Bois, Philipp Harter, et al.
ESMO Open
|
December 14, 2020
First-line PARP inhibitors in ovarian cancer: summary of an <i>ESMO Open - Cancer Horizons</i> round-table discussion
Susana Banerjee, Antonio Gonzalez-Martin, Philipp Harter, et al.
Annals of Surgical Oncology
|
April 2, 2021
Association Between Adjuvant Therapy and Survival in Stage II-III Endometrial Cancer: Influence of Malignant Peritoneal Cytology
Koji Matsuo, Shinya Matsuzaki, David J Nusbaum, et al.
Investigational New Drugs
|
September 6, 2013
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)
Philipp Harter, Jalid Sehouli, Rainer Kimmig, et al.
Archives of Gynecology and Obstetrics
|
February 20, 2016
The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications
Ivo Meinhold-Heerlein, Christina Fotopoulou, Philipp Harter, et al.
Expert Review of Anticancer Therapy
|
July 24, 2013
Adjuvant therapy in node-positive vulvar cancer
Sven Mahner, Fabian Trillsch, Lilli Kock, et al.
Archives of Gynecology and Obstetrics
|
September 21, 2018
Is there a role for HIPEC in ovarian cancer?
Philipp Harter, Andreas du Bois, Jalid Sehouli, et al.
Page
of 28